Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 46 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Dupilumab for treating Chronic obstructive pulmonary disease (COPD)	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Chronic obstructive pulmonary disease (COPD)	Respiratory System	2022	View \| Download
Dupilumab in addition to controller medications for children aged 6 to 11 years with asthma	controller medications , Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Asthma	Respiratory System	2021	View \| Download
Elexacaftor/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one minimal function mutation in patients aged 6 to 11 years	Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Elexacaftor/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation in patients aged 12 years old and older	Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Tezacaftor (VX-661)	Cystic fibrosis	Genetic Disorders , Respiratory System	2020	View \| Download
Elexacaftor/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 6 to 11 years old	Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Elexacaftor/tezacaftor/ivacaftor and ivacaftor for treating cystic fibrosis without an F508del mutation and with an ELX/TEZ/IVA-responsive mutation in the CFTR gene in patients aged 6 years and older	Ivacaftor (Kalydeco; VX-770) , Kaftrio (fixed dose combination: Elexacaftor; Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2023	View \| Download
Fevipiprant maintenance therapy for uncontrolled asthma – add on therapy	Fevipiprant (QAW-039)	Asthma	Respiratory System	2019	View \| Download
Gefapixant for chronic refractory cough – First line	Gefapixant (MK-7264)	Idiopathic chronic cough	Respiratory System	2020	View \| Download
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease including combined pulmonary fibrosis and emphysema	Treprostinil (Tyvaso; LIQ861; Orenitram; UT-15C; Remodulin; treprostinil sodium)	Pulmonary hypertension	Cardiovascular System , Respiratory System	2024	View \| Download
Ivacaftor for cystic fibrosis in infants	Ivacaftor (Kalydeco; VX-770)	Cystic fibrosis	Genetic Disorders , Respiratory System	2023	View \| Download